News Column

New Depression Findings from Institute of Nuclear Medicine and Allied Sciences Described (Pharmacoscintigraphic evaluation of potential of lipid...

August 6, 2014



New Depression Findings from Institute of Nuclear Medicine and Allied Sciences Described (Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Mental Health. According to news reporting from Delhi, India, by NewsRx journalists, research stated, "Efficacy of antidepressants relies upon their continued presence at the site of action (brain) over a prolonged period of time. The BBB restricts the access of antidepressants to the brain on oral as well as intravenous administration."

The news correspondents obtained a quote from the research from the Institute of Nuclear Medicine and Allied Sciences, "Direct delivery (by-passing the BBB) of antidepressant drugs can increase the CSF concentration with concomitant reduction in dose and side effects. Intranasal administration of nanostructured lipid carriers (NLC) containing antidepressant drug circumvent the BBB and maintain the prolonged release at the site of action. The aim of the present study-was to evaluate the enhancement in brain uptake of NLC containing duloxetine (DLX) after intranasal administration. Duloxetine loaded NLC (DLX-NLC) was evaluated pharmacoscintigraphically for drug targeting potential (DTP), drug targeting efficiency (DTE) and biodistribution studies in different organs including brain. The radiolabeling efficiency of DIX and DLX-NLC was found to be 98.41 +/- 0.96 and 98.87 +/- 0.82 after 30 min, respectively. The biodistribution studies exhibited higher percentage of radioactivity/g for DLX-NLC formulations in brain as compared with the DLX. The higher DTP (86.80%) and DTE (757.74%) suggested that DLX-NLC formulation has a better brain targeting efficiency than DLX solution (DTP = 65.12%; DTE = 287.34%) when administered intranasally. Moreover, the intranasal administration exhibited about 8-times higher concentration of DLX in brain when compared with the intravenous administration of DLX solution."

According to the news reporters, the research concluded: "The intranasal NLC containing DIX can be employed as an effective method for the treatment of depression."

For more information on this research see: Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. International Journal of Pharmaceutics, 2014;470(1-2):99-106. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)

Our news journalists report that additional information may be obtained by contacting M.I. Alam, Inst Nucl Med & Allied Sci, Dept. of Nucl Med, Delhi, India. Additional authors for this research include S. Baboota, A. Ahuja, M. Ali, J. Ali, J.K. Sahni and A. Bhatnagar (see also Mental Health).

Keywords for this news article include: Asia, Antidepressants, Delhi, India, Therapy, Nanocarriers, Mental Health, Nanotechnology, Emerging Technologies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters